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 ABSTRACT 
TRPA1 is a non-selective cation channel, most famously expressed in non-myelinated nociceptors. 
In addition to being an important chemical and mechanical pain sensor, TRPA1 has more recently 
appeared to have a role in inflammation as well. Triterpenoids are natural products with anti-
inflammatory and anti-cancer effects in experimental models. In this paper, thirteen novel 
triterpenoids were created by synthetically modifying betulin, an abundant triterpenoid of the genus 
Betula L. and their TRPA1-modulating features were examined. Fluo 3-AM protocol was used in 
the initial screening, in which six out of the fourteen tested triterpenoids inhibited TRPA1 in a 
statistically significant manner. In subsequent whole-cell patch clamp recordings, the two most 
effective compounds (pyrazine-fused triterpenoids 8 and 9) displayed a reversible and dose and 
voltage-dependent effect to block the TRPA1 ion channel at submicromolar concentrations. 
Interestingly, the TRPA1-blocking action was also evident in vivo, as compounds 8 and 9 both 
alleviated TRPA1-agonist induced acute paw inflammation in mice. The results introduce betulin-
derived pyrazine-fused triterpenoids as promising novel antagonists of TRPA1 that are potentially 
useful in treating diseases with a TRPA1-mediated adverse component. 
KEYWORDS: Transient receptor potential channels, TRPA1, inflammation, pain, natural 
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 INTRODUCTION 
Transient receptor potential ankyrin 1 (TRPA1) is a cation channel expressed predominantly in Aδ- 
and C-type nociceptive nerve fibers mediating chemical and mechanical pain. TRPA1 is a 
physiological chemoreceptor for potentially harmful exogenous chemicals and its activation causes 
immediately perceivable and often painful sensations.1,2 Indeed, there are many naturally occurring 
irritants that activate TRPA1 e.g. allicin in garlic (Allium sativum L.), cinnamaldehyde in cinnamon 
(Cinnamomum Schaeff.) and allyl isothiocyanate (AITC) in mustard oil.3-5 
There is increasing data supporting the idea that TRPA1 ion channel also plays a critical role in 
inflammation.1 Pharmacological blockade and genetic deletion of TRPA1 have been shown to 
alleviate nociception and inflammation in animal models such as carrageenan-induced paw 
inflammation,6 monosodium iodoacetate-induced arthritis,7 monosodium urate crystals-induced 
gouty arthritis and formalin-induced pain.8-10 These adverse effects of TRPA1 activation were not 
due to a direct effect of the disease-inducing exogenous substance on the ion channel but 
attributable to endogenous activation of TRPA1. Indeed, endogenous compounds capable of 
opening the TRPA1 channel have recently been characterized and they include factors released in 
inflammatory conditions such as reactive oxygen and nitrogen species (ROS and RNS), bradykinin 
and some prostaglandins.5,11 The emerging dualistic role of TRPA1 in nociception and 
inflammation has revealed TRPA1 as a promising drug target. It has been speculated that blockade 
of TRPA1 is likely to provide direct alleviation of pain and additionally attenuate inflammation. 
However, although there is a wide spectrum of compounds known to activate TRPA1, only a few 
blockers have been identified. 
Betulin (1) is a widely studied triterpenoid, which can be found in the birch tree bark (Betula sp. 
L.). Other triterpenoids are present in olives and apple peel and are thought to contribute to some of 
the health promoting effects of these foodstuffs: Betulin (1) and some related triterpenoids have 
 been found to possess anti-inflammatory properties.12-15 There is also evidence of their therapeutic 
potential against cancer, HIV and protozoal diseases.16-25 
Based on our preliminary screening results, we postulated that some of the pharmacological features 
of triterpenoids might be attributable to blockade of TRPA1. In the present study, we utilized two in 
vitro protocols: the Fluo 3-AM intracellular Ca2+ measurement and whole-cell patch clamp current 
recording, as well as an in vivo model of acute TRPA1-mediated inflammation to study the effects 
of betulin (1) and a series of its derivatives (2 – 14) on TRPA1.  
 RESULTS  
Chemistry. Thirteen triterpenoids 2-14 were synthesized as described previously and their 
structures are shown in Figure 1, along with betulin (1).20-22 In addition, a novel method to convert 
betulin to betulonic and further to betulinic acid was developed (Figure 2): First, betulin (1) was 
oxidized to betulonic aldehyde with air using palladium(II) acetate as a catalyst. The resulting 
betulonic aldehyde was further oxidized to betulonic acid (2) in one pot using sodium chlorite as an 
oxidant. Finally, the reduction of betulonic acid (2) with NaBH4 produced betulinic acid (3) with a 
good yield. 
Six of the fourteen triterpenoids inhibit TRPA1 in vitro. The antagonistic properties of the 
triterpenoids on TRPA1 were first screened at 10 µM concentrations using the Fluo 3-AM calcium 
measurement protocol in human TRPA1 (hTRPA1) transfected HEK293 cells. The cells were pre-
incubated with the triterpenoids and thereafter TRPA1-mediated Ca2+-influx was induced by adding 
the known TRPA1 activator AITC.  
Six triterpenoids, namely compounds 5, 6, 7, 8, 9 and 14 inhibited AITC-induced Ca2+influx at 10 
µM concentration in a statistically significant manner. The results of the TRPA1-blocking activity 
of all triterpenoids studied are summarized in Table 1. The cytotoxicity of the compounds in the 
experimental conditions used was ruled out with the XTT assay. 
The two most promising compounds 8 and 9 (Figure 3) were examined further in a broader range of 
concentrations up to 100 µM and a dose-dependent inhibition was observed with both compounds 
(Figure 4). The IC50 values of compounds 8 and 9 in the Fluo 3-AM Ca
2+-influx measurements 
were 9.5 and 7.5 µM, respectively. 
Further experiments demonstrated that the triterpenoids 8 and 9 blocked AITC-induced Ca2+-influx 
also in HEK293 cells transfected with mTRPA1 (Figure 5). In addition, compounds 8 and 9 at 
 concentrations up to 100 µM did not induce any detectable Ca2+-influx in HEK293 cells transfected 
with either human or mouse TRPA1, ruling out an agonistic effect. 
In whole-cell patch clamp recordings, triterpenoids 8 and 9 display a strong and reversible 
TRPA1-blocking activity. To verify the TRPA1 blocking ability of compounds 8 and 9, we 
utilized the whole-cell patch clamp recording technique. In HEK293 cells transfected with 
hTRPA1, the AITC (50 µM)-induced ion currents through TRPA1 were strongly attenuated at a 
holding potential of -50 mV when the cells were treated with either compound 8 or 9 (Figure 6A 
and 6C). Interestingly, both compounds exerted a voltage-dependent blockade of TRPA1 channel 
currents (Figure 6B and 6D). The IC50 values of compounds 8 and 9 against HC-030031 sensitive 
TRPA1 channel currents at -100 mV and -50 mV were each 0.3 μM, whereas at +50 mV they were 
1.3 μM, and at +100 mV, they were 1.8 μM and 4.4 μM, respectively (Figure 6E and 6F). 
In additional experiments, we examined the reversibility of the inhibitory effects of compounds 8 
and 9 on TRPA1. Since high concentrations of AITC may desensitize TRPA1 during the 
recordings, we exploited 10 μM AITC to activate TRPA1 in these experiments. As shown in Figure 
7A-H, both pyrazine-fused triterpenoids (compounds 8 and 9) exhibited inhibitory effects on 10 μM 
AITC-induced currents at a holding potential of -50 mV comparable to those seen with the 50 μM 
AITC-induced currents (see also Figure 6E and 6F). This suggests that the concentration of the 
TRPA1 agonist had little or no influence on the inhibitory effect of compounds 8 and 9. After the 
current amplitude had stabilized during the application of compounds 8 and 9, they were removed 
from the bathing solution while maintaining 10 μM AITC. The recovery of AITC-induced TRPA1 
activation was complete after the withdrawal of 0.3 and 3 μM concentrations of compounds 8 and 
9; while the recovery was partial, but still obvious, after 30 µM concentrations of compounds 8 and 
9 (Figure 7C, 7F, 7G and 7H). This demonstrates that compounds 8 and 9 are reversible blockers of 
hTRPA1 at concentrations up to 3 μM, but at 30 µM concentration the blockade is partially 
irreversible. 
 Triterpenoids 8 and 9 attenuate TRPA1-mediated acute inflammation in vivo. As compounds 8 
and 9 were highly promising TRPA1 blockers in vitro, we determined whether they could inhibit 
TRPA1-mediated inflammation in vivo. Hence, the effects of compound 8 and 9 on AITC-induced 
acute inflammation were investigated in the mouse paw edema model. The mice were injected 
intraplantarly with the TRPA1 agonist AITC and the increase in the volume of the paw caused by 
the inflammatory edema was measured in mice pre-treated with the compounds and compared with 
those receiving vehicle only. Systemically administered compounds 8 (10 mg/kg, i.p.) and 9 (10 
mg/kg, i.p.) both attenuated the AITC-induced inflammatory edema with an effect similar to the 
known TRPA1 antagonist HC-030031 (300 mg/kg, i.g.), used as a positive control. The results are 
summarized in Figure 8. 
  
  
DISCUSSION 
The present results clearly indicate that the two pyrazine-fused triterpenoids, compounds 8 and 9 
(Figure 3), effectively inhibit TRPA1 activation in a dose-dependent manner in vitro and 
significantly attenuate acute inflammation mediated by TRPA1 in vivo. The observed blockade of 
both human and mouse TRPA1 channel in vitro suggests that the compounds’ inhibitory effects on 
TRPA1-mediated conditions in mice are likely to be generalized to humans as well. Furthermore, in 
the whole-cell patch clamp recordings, the blocking effect of the compounds was completely 
reversible up to the concentrations of 3 µM. 
The in vivo experiments demonstrated that compounds 8 and 9 attenuated TRPA1-mediated 
inflammation induced by AITC, indicating that these two triterpenoids when administered 
systemically have appropriate pharmacokinetics to ease paw inflammation, most likely by inhibiting 
TRPA1 activation. It is noteworthy that the two triterpenoids were active at doses lower than the 
widely used TRPA1 antagonist HC-030031. Mice exhibited no adverse effects due to treatment 
with the triterpenoids during the short duration of the experiment. 
The detailed molecular mechanism of action of pyrazine-fused triterpenoids (compounds 8 and 9) 
on TRPA1 channel cannot be determined based on the results of the present study though both 
triterpenoids inhibited the channel currents in a voltage-dependent manner. Previous studies on 
TRPA1 blockers have revealed versatile binding sites and mechanisms of actions: a very effective 
TRPA1 antagonist A-967079 seems to attach to the TRPA1 channel pore vestibule where it 
interacts with the phenyl moiety of F944,26 the site of HC-030031 action is the N855 residue of the 
channel and interaction with the C-terminus region exerts synergistic effects on the inhibition.27 
Since compounds 8 and 9 exerted voltage-dependent blockade against TRPA1, it is possible that 
these triterpenoids interact with certain amino acid residues in the channel which are located close 
 to the electrical fields within the plasma membrane. In addition, HC-030031 has been reported to be 
a rapidly acting and reversible blocker.10 Menthol is a terpene related compound, which has been 
shown to have an effect on TRPA1. Its binding site in mouse TRPA1 has been reported to be 
transmembrane domain 5, which is essential for the channel’s ability to sense menthol. Nine other 
pore residues were also identified to account for the species-specific alteration of menthol’s action 
as either agonist or antagonist of TRPA1.28 
In the present study, we showed that the effects of the compounds 8 and 9 were reversible at least 
up to the concentration of 3 μM, while their action was only partly reversible at 30 μM 
concentration. Moreover, the recovery after the removal was relatively slow even at 0.3 μM, 
suggesting that these triterpenoids bind tightly to the TRPA1 channel. Since both compounds 8 and 
9, but not the other triterpenoids investigated, have a pyrazine ring in their structure (Figure 1), this 
moiety appears to be critical for their blocking efficacy, reversibility and/or recovery rate after their 
removal. The conversion of the carboxylic acid in compound 8 to the respective amide in compound 
9 did not seem to affect the TRPA1 blocking properties of the compound. Even though the pyridine 
derivative compound 10 did not exert a blockade similar to compounds 8 and 9, the effects of other 
six-membered rings on the 2,3-position should be determined in the future. Further extensive 
studies will be required to clarify the detailed molecular mechanisms of TRPA1-blocking by 
pyrazine-fused triterpenoids. 
The IC50 values of compounds 8 and 9, around 0.3 µM each at -50 mV in whole-cell patch clamp 
recordings against 50 μM AITC, were lower than that of the most widely used TRPA1 blocker HC-
030031 (~1 µM against 5 μM AITC-induced human TRPA1 currents).10 However, the IC50 values 
calculated from intracellular Ca2+ influx measurements were higher: 9.5 and 7.5 µM for compounds 
8 and 9, respectively. Similarly, the IC50 value of HC-030031 was higher in the Ca
2+ measurement 
assay (6.2 μM) than in the patch clamp experiments.10 It is also notable that IC50 values of 
compounds 8 and 9 were increased at positive membrane potentials in whole-cell patch clamp 
 experiments. This depolarization-induced reduction in the blockade of TRPA1 by both compounds 
8 and 9 may in part explain the difference in IC50 values between Fluo 3-AM and whole-cell patch 
clamp experiments. The activation of TRPA1 induces depolarization of TRPA1-expressing HEK 
293 cells in the Fluo 3-AM experiments and thus may attenuate the blocking efficacy of compounds 
8 and 9 against TRPA1.  For comparison to the identified IC50 value of 0.3 µM for betulin -derived 
compounds 8 and 9, the naturally occurred stilbenoids pinosylvin and resveratrol have been shown 
to block TRPA1 activity with IC50 of 16.7 µM and 12,9 µM, in whole-cell patch clamp recordings, 
respectively,29 and gallic acid with IC50 of 11 µM.
30 Recently described synthetically modified 
quinazolinone-based purinone 27 and N-isopropylglycine sulfonamide-based Compound 20 have 
increased potency while the most widely used traditional TRPA1 blockers are less potent than the 
compounds 8 and 9 identified in the present study.31,32 
Laavola et al. have recently assessed the anti-inflammatory properties of compounds 8 and 9.15 A 
significant decrease of inducible nitric oxide synthase (iNOS) expression was observed in J774 
macrophages treated with both compounds, which is likely to result in impaired production of nitric 
oxide (NO) in inflammatory conditions. As NO is a known TRPA1 activator,11 compounds 8 and 9 
may down-regulate TRPA1-mediated responses in inflammatory conditions both directly by 
blocking the channel (as shown in the present study) and indirectly by reducing the synthesis of 
endogenous TRPA1 activators such as NO. Moreover, the antagonistic effects of compounds 8 and 
9 on TRPA1 channels may at least partially explain the previously reported attenuating effects of 
these compounds on inflammatory gene expression,15 because TRPA1 activation has been shown to 
up-regulate the expression of pro-inflammatory factors, like cyclo-oxygenase-2, and interleukins 1, 
6, and 8 in inflammatory conditions.6,7,33-35 
The present results have laid the foundation for a wider assessment of the effects of pyrazine-fused 
triterpenoids in different animal models of diseases involving TRPA1 activation. If one considers 
the positive effects of other TRPA1 blockers, treatment of neuropathic pain has travelled the longest 
 path; phase II clinical trials of the compound GRC 17536 have been conducted, with favorable 
results.36 Some novel directions in TRPA1 research have emerged: TRPA1 has a notable role in the 
pathogenesis of allergic contact dermatitis and therefore TRPA1 blockers might be useful in its 
treatment.37 Our recent studies have shown that in primary human articular chondrocytes TRPA1 is 
expressed and that TRPA1 blockers and/or genetic deletion of TRPA1 can alleviate pain and 
inflammation in experimental models of osteoarthritis and gout.7,8,33 Other inflammatory conditions 
such as colitis and asthma are also potential targets of TRPA1 blockers.38,39 The most widely used 
TRPA1 blocker in animal experiments, HC-030031, was unfortunately discovered to possess poor 
pharmacokinetic properties.40 Therefore, the pharmacokinetic profile as well as the safety profile of 
compounds 8 and 9 should be characterized in the future, although our preliminary data did not 
reveal any obvious concerns. 
In conclusion, this study discovered two pyrazine-fused triterpenoids (compounds 8 and 9) which 
were found to block the TRPA1 ion channel reversibly in vitro and alleviate TRPA1-mediated 
inflammation in vivo. They could be useful lead compounds when developing new drugs for 
alleviating TRPA1-mediated adverse conditions. 
 METHODS 
Triterpenoid synthesis 
General Experimental Procedures. Commercially available reagents were used without further 
purification. Crude betulin (UPM, Lappeenranta, Finland) was recrystallized from 2-propanol/H2O 
azeotrope to yield 99% pure betulin as a white solid. All solvents were of HPLC grade. Anhydrous 
solvents were purchased from Sigma-Aldrich (St. Louis, MO, USA). All reactions in anhydrous 
solvents were performed in oven-dried glassware under an inert atmosphere of anhydrous argon or 
nitrogen. Thin-layer chromatography (TLC) was performed on E. Merck (Darmstadt, Germany) 
silica gel 60 backed plates, with visualization by UV illumination and staining with 5% H2SO4 in 
MeOH. Melting points were obtained with a Sanyo Gallenkamp (Moriguchi, Osaka, Japan) 
apparatus without correction. The Fourier transform infrared (FTIR) spectra were recorded on a 
Nicolet iS50 FT-IR (Waltham, MA, USA) using a built-in diamond ATR. The 1H and 13C NMR 
spectra were measured on a Bruker Avance III 500 MHz NMR spectrometer (Billerica, MA, USA). 
1H and 13C NMR spectra were recorded in solution, in CDCl3. HRMS were measured to determine 
the purity of all tested compounds on a Waters Acquity UPLC system (Waters, Milford, MA, USA) 
equipped with a Synapt G2 HDMS mass spectrometer (Waters). 
Triterpenoids. A novel method was developed to synthesize betulonic and betulinic acid from 
betulin, as detailed below. The other 11 betulin derivatives were prepared as described previously 20-
22. 
Betulonic acid (2). Palladium(II) acetate (1.2 g, 6 w-%) and pyridine (5 mL) were added to toluene 
(500 mL). Mixture was heated to 80 °C and betulin (1) (20.0 g, 45.2 mmol) was added in small 
portions under vigorous stirring and air bubbling (flow rate 1000 mL/min). After 7 h, the reaction 
was quenched (monitored by GC) by adding N-acetyl-L-cysteine (8.0 g, 66.0 mmol) to scavenge 
Pd(II). The reaction mixture was cooled to room temperature, and the residue was filtered and washed 
 with toluene (3 × 20 mL). The resulting filtrate containing betulonic aldehyde was used in the next 
reaction step in one pot without further purification. tert-Butanol (170 mL) and 2-methyl-2-butene 
(30 mL) were added to the filtrate (containing 20 g of betulonic aldehyde, GC purity 88%) under N2 
flow. NaClO2 (80%, 17.0 g, 150 mmol) and NaH2PO4H2O (25.2 g, 183 mmol) in water (200 mL) 
were added during 30 min and stirring was continued at RT under N2 atmosphere for 15 h. The organic 
and aqueous phases were separated and 1.7 M solution of NaOH in H2O (40 mL) was added to the 
organic phase and stirred for 0.5 h. Half of the solvent was evaporated off in vacuo and the formed 
precipitate was filtered, washed with toluene (4 × 20 mL) and dried overnight in vacuo to yield sodium 
betulonate (16.6 g, 36.0 mmol). Sodium betulonate was treated with a 3% solution of HCl in H2O 
(200 mL) and the resulting mixture was stirred for 2.5 h. The formed precipitate was filtered and 
washed with water (5 × 30 mL), dried in vacuo at 60 C overnight to give betulonic acid (14.9 g, 32.8 
mmol), in 73% yield from betulin. Spectral data was identical to that reported in the literature 21. 
Betulinic acid (3). Betulonic acid (2) (13.0 g, 28.6 mmol) was added to a mixture of water (130 
mL), 5% solution of NaOH in H2O (26 mL) and 2-propanol (120 mL). NaBH4 (1.20 g, 31.7 mmol) 
was added and the reaction mixture was stirred for 3 h in an ice bath. The alkaline solution was 
acidified by adding 10% solution of HCl in H2O (130 mL). The precipitated betulinic acid was 
filtered, washed with water (4 × 50 mL) and dried in vacuo to yield crude betulinic acid (12.2 g, 
94%). A batch of crude betulinic acid (5.0 g) was dissolved in refluxing ethanol (50 mL) and 
allowed to crystallize at 4 C overnight. The formed crystals were filtrated and dried in vacuo to 
produce very pure betulinic acid (4.1 g, 9.0 mmol) in 82% yield. Spectral data was identical to that 
reported in the literature 21.  
 Effects of triterpenoids on TRPA1-mediated responses 
Reagents. Reagents (unless otherwise indicated) were provided by Sigma Chemical Co., St. Louis, 
MO, USA. 
Cell culture. HEK293 human embryonic kidney cells (American Type Culture Collection, 
Manassas, VA, USA) were cultured at 37 °C in 5% CO2 in Eagle’s Minimum Essential Medium 
(EMEM) supplemented with fetal bovine serum (10%), sodium pyruvate (1 mM), sodium 
bicarbonate (1.5%), non-essential amino acids (1 mM each, all from Lonza, Verviers, Belgium), 
streptomycin (100 mg/mL), penicillin (100 U/mL) and amphotericin B (all from Invitrogen, Paisley, 
UK). Cells were cultivated on a 96-well plate and transfected transiently with hTRPA1 (0.2 
µg/well, pCMV6-XL4; Origene, Rockville, MD, USA) or mTRPA1 plasmid (0.2 µg/well, 
Mm17807; Gene Copoeia Inc., MD, USA). The cells were transfected 20 h before the experiments 
were started with Lipofectamine 2000 (Invitrogen, 0.5 µL/well).  
Intracellular Ca2+ measurements. For intracellular Ca2+ measurements, transiently transfected 
HEK293 cells were loaded with Fluo 3 acetoxymethyl (AM) ester [2.5 µM Fluo 3-AM in Hanks’ 
Basic Salt Solution (Lonza, Verviers, Belgium) pH 7.45 with 25 mM HEPES, 1 mg/mL bovine 
serum albumin, 2.5 mM probenecid and 0.08% Pluronic F-127®], for 40 min, at RT. Thereafter, the 
cells were washed and buffer solution containing the studied compounds was added to the wells and 
the cells were incubated for 30 min at 37 °C. Free intracellular Ca2+ concentrations were measured 
with a Victor3 1420 multi-label counter (Perkin Elmer, Waltham, MA, USA) at wavelengths of 
em485/ex535 nm. Basal level of fluorescence was measured for 15 s before adding the TRPA1 
agonist allyl isothiocyanate (AITC, 50 µM) and thereafter the measurements were continued for 30 
s. Finally, ionomycin (1 µM), was applied to induce a robust Ca2+-influx. The TRPA1-opening 
properties of the compounds were measured using the same protocol with the exception of adding 
the compounds of interest instead of AITC. In these measurements, AITC (50 µM) was used as a 
 positive control and the TRPA1 antagonist HC-030031 (100 – 200 µM) was utilized to estimate the 
TRPA1 mediation of Ca2+-influx. 
The cytotoxic effects of all the triterpenoids studied were evaluated with the modified XTT test 
(Cell Proliferation Kit II; Roche Diagnostics, Mannheim, Germany).  
Whole-cell patch clamp recordings. Whole-cell patch clamp recordings were performed on 
HEK293 cells transiently transfected with a plasmid encoding hTRPA1 (pIRES2-AcGFP1; Takara, 
Tokyo, Japan). The cells successfully expressing TRPA1 were identified using green fluorescent 
protein. The resistance of electrodes was 3–7 MΩ when filled with a solution mimicking 
intracellular conditions (CsCl 30 mM, Cs aspartate 110 mM, MgCl2 1 mM, EGTA 10 mM, HEPES 
10 mM, CaCl2 6.25 mM, ATP disodium salt 2 mM, adjusted to pH 7.2 with CsOH). Membrane 
currents and voltage signals were converted into a digital form using an analog–digital converter 
(PCI6229; National Instruments Japan Corporation, Tokyo, Japan). Data acquisition and current 
imaging of whole-cell currents were performed using WinEDR V3.38 developed by Dr. John 
Dempster (University of Strathclyde, UK). A ramp voltage protocol from -150 mV to +100 mV of 
100 ms was applied every 5 s from a holding potential of -50 mV. A HEPES-buffered bathing 
solution (CsCl 10 mM, KCl 5.9 mM, NaCl 137 mM, glucose 14 mM, MgCl2 1.2 mM, HEPES 10 
mM, adjusted to pH 7.4 with NaOH) was used. All experiments were performed at 25 ± 1 °C, and 
the studied drugs, AITC (10 and 50 μM), compound 8 (0.3 – 100 µM), compound 9 (0.3 – 100 µM), 
HC-030031 (30 µM), and A-967079 (5 μM) were dissolved in dimethyl sulfoxide (final 
concentration ≤ 0.13%). 
In vivo model of TRPA1-mediated inflammation. Male C57BL/6N mice were obtained from 
Scanbur Research A/S, Karlslunde, Denmark. The mice were housed at the Tampere University 
animal facility (12:12 h light:dark cycle, temperature 22 ± 1 °C, food and water provided ad 
libitum). Animal experiments were carried out in accordance with the institutional, national and 
European (Directive 2010/63/EU) legislation for the protection of animals used for scientific 
 purposes and approved by the National Animal Experiment Board. Anaesthesia was performed with 
ketamine (75 mg/kg, i.p., Ketalar®; Pfizer Oy Animal Health, Helsinki, Finland) and medetomidine 
(0.375 mg/kg, i.p., Domitor®; Orion Oyj, Espoo, Finland). 
The specific TRPA1 agonist AITC was used to induce inflammatory paw edema by injecting 50 µL 
of sterile endotoxin-free PBS containing 15 mM AITC into the hind paw of anaesthetized mice. The 
contralateral paw was injected with the corresponding volume of the vehicle. Prior to the injection 
of AITC, the mice were dosed with either compound 8 or 9 (both 10 mg/kg in PBS/10% DMSO 
given intraperitoneally 1 h before AITC), or with the vehicle or with the known TRPA1 antagonist 
HC-030031 [300 mg/kg in 50% polyethylene glycol, 40% 1,2-propanediol and 10% Glucosteril 50 
mg/mL (Baxter Oy, Vantaa, Finland) given intragastrically 2 h before AITC]. The paw volumes 
were measured before and 3 and 6 h after the AITC injections with a plethysmometer (Ugo Basile, 
Comerio, Italy). The volume change in the vehicle-injected control paw was subtracted from the 
volume change in the AITC-injected paw and the results are given in µL.  
Statistical analysis 
The statistical significance of the results was analysed with GraphPad InStat® 3.10 for Windows 
(GraphPad Software, Inc. San Diego, CA, USA) and with Origin9.1J (OriginLab, Northampton, 
MA, USA) using two-way or one-way ANOVA with Dunnett’s, Bonferroni’s or Tukey’s multiple 
comparison test. The results are expressed as mean  SEM (standard error of the mean) with 
*=p<0.05, **=p<0.01 and ***=p<0.001.  
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 Table legends 
Table 1 
The effect of triterpenoids (10 µM) on allyl isothiocyanate (AITC, 50 µM)-induced TRPA1 
activation measured by Ca2+ influx in HEK293 cells transfected with a plasmid encoding hTRPA1. 
TRPA1-inhibition by triterpenoids is presented as a percentage of the area under curve (AUC) in 
relation to the untreated AITC control. Results are expressed as mean ± SEM, *p < 0.05, **p < 0.01 
and ***p < 0.001. 
  
 Figure legends 
Figure 1 
Structural formulae of betulin and its triterpenoid derivatives. 
 
Figure 2 
Synthesis of betulonic (2) and betulinic (3) acid from betulin (1). Reagents and conditions: (a) 
Pd(OAc)2, py, toluene, air, 80 C, 7 h; (b) NaClO2, NaH2PO4H2O, 2-methyl-2-butene, tert-butanol, 
H2O, rt, 12 h; (c) NaBH4, NaOH, H2O, 2-propanol, 0 C, 3 h. 
 
Figure 3 
Structural formulae of the key triterpenoids 8 and 9. 
 
Figure 4 
Compounds 8 and 9 inhibited allyl isothiocyanate (AITC, 50 µM)-induced Ca2+-influx in 
HEK293 cells transfected with a plasmid encoding hTRPA1 in a dose-dependent manner. Fluo 
3-AM loaded cells were pre-incubated for 30 min with compound 8 (1 – 100 µM), compound 9 (1 – 
100 µM) or with the known TRPA1 antagonist HC-030031 (100/200 µM) before intracellular Ca2+ 
measurement. A and C show representative curves displaying relative fluorescence units after 
treatment with compounds 8 and 9, respectively. B and D show the areas under curve (AUC; from 
15 to 45s) of the response to AITC with or without compound 8 and 9 treatments, respectively. 
Background fluorescence was recorded for 15 s before the addition of the TRPA1 agonist AITC. 
Fluorescence increase in response to AITC was measured for 30 s after which the control 
ionophore, ionomycin (1 µM), was added and fluorescence was measured for another 30 s. The 
results are normalized to the background and expressed as mean + SEM, n = 6 – 8, *p < 0.05, **p < 
0.01 and ***p < 0.001. 
  
Figure 5 
Triterpenoids 8 and 9 inhibited allyl isothiocyanate (AITC, 50 µM) induced Ca2+ influx in 
HEK293 cells transfected with a plasmid encoding mTRPA1. Fluo 3-AM loaded cells were pre-
incubated for 30 min with compound 8 (100 µM), compound 9 (100 µM) or with the known 
TRPA1 antagonist HC003031 (100 µM). In A and B, the areas under curve (AUC) of the 
fluorescence response to AITC with or without 8 and 9 treatment, respectively, are presented. 
Background fluorescence was recorded for 15 s before addition of AITC. The increase in 
fluorescence in response to AITC was measured for 30 s. The results are normalized to background 
and expressed as mean + SEM, n = 5-8, *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Figure 6 
Triterpenoids 8 and 9 inhibited allyl isothiocyanated (AITC) -induced membrane currents 
measured with whole-cell patch clamp recording in HEK293 cells transfected with hTRPA1. 
In A and C, the current trace displays the change of inward currents at -50 mV which was evoked 
by compounds 8 (0.3, 3, and 30 μM) and 9 (0.3, 3, and 30 μM), respectively, in the presence of 50 
μM AITC. To determine the zero current level of TRPA1 components, 30 μM HC-030031 (HC) 
was applied at the end of each experiment. In B and D, a current-voltage (I-V) relationship was 
constructed to use a ramp waveform pulse from -150 to +100 mV for 100 ms. Six I-V relationships 
were illustrated before (cont) and after application of AITC (50 μM AITC), and during 
simultaneous application of 0.3, 3, or 30 μM compound 8 (+30 μM 8) and 50 μM AITC in B. The 
experimental conditions in D were identical to those utilized in B except for application of 
compound 9. In E and F, each relative amplitude (relative) was calculated as a current size at -100, 
-50, +50, and +100 mV between before and after application of 8 and 9, respectively, and 
 summarized as a dose-response relationship. Maximum and minimum amplitudes of the current 
were obtained in the presence of AITC (1.0) and in the presence of both AITC and HC-030031 (0). 
The results in E and F are expressed as mean ± SEM. * = p < 0.05 by two-way ANOVA. In E and 
F, the numbers of replicates are described in parentheses next to the markers. 
 
Figure 7 
Recovery of allyl isothiocyanate (AITC) -induced membrane currents after removal of 
compounds 8 and 9. In A and D, the trace displays the change of inward currents at -50 mV which 
was evoked by application and removal of compounds 8 (0.3 μM) and 9 (0.3 μM), respectively, in 
the presence of 10 μM AITC. To determine the zero-current level of TRPA1 components, the 
known TRPA1 antagonist A-967079 (A96, 5 μM) was applied at the end of each experiment. The 
experimental conditions in B and E and in C and D were identical to those utilized in A and D 
except for the concentration of compounds 8 and 9 at 3 μM and 30 μM, respectively. In G and H, 
the relative amplitude was calculated as a current size at -50 mV between the zero current and the 
current amplitude before and after application of each compound, and after their removal but still in 
the presence of AITC. The results in G and H are expressed as mean ± SEM, * = p < 0.05 against 
each first column and # = p < 0.05 against each second column, tested by Tukey's multiple 
comparison test. In G and H, the numbers of replicates are described in parentheses above the 
columns. 
 
Figure 8 
Triterpenoids 8 and 9 inhibited TRPA1-mediated acute paw inflammation in mice. Mice were 
pre-treated with compound 8 (10 mg/kg, i.p.), compound 9 (10 mg/kg, i.p.), the known TRPA1 
blocker HC-030031 (300 mg/kg, i.g.) or with the vehicle at 1 h (8, 9 and vehicle) or 2 h (HC-
 030031) prior to the subcutaneous administration of the TRPA1 agonist allyl isothiocyanate (AITC) 
in the paw. The paw volume was measured with a plethysmometer before and 3 and 6 h after AITC 
paw injection. The results are normalized to the control paw injected with the vehicle. Mean + 
SEM, n = 6, *p < 0.05, **p < 0.01, ***p < 0.001  
 Tables 
Table 1 
  
  
Compound  % of control 
control  100 
HC-030031 (100 µM)  22.24 ±2.2 *** 
   
1 (10 µM)  98.89 ±4.0  
2 (10 µM)  83.32 ±8.9  
3 (10 µM)  83.65 ±3.9  
4 (10 µM)  83.42 ±5.0  
5 (10 µM)  85.52 ±3.2 * 
6 (10 µM)  79.08 ±3.2 ** 
7 (10 µM)  79.55 ±4.2 ** 
8 (10 µM)  61.32 ±3.1 ** 
9 (10 µM)  64.09 ±4.0 ** 
10 (10 µM)  85.65 ±15.1  
11 (10 µM)  86.48 ±6.6  
12 (10 µM)  96.48 ±6.3  
13 (10 µM)  96.90 ±6.8  
14 (10 µM)  75.50 ±6.0 ** 
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